Trials / Completed
CompletedNCT01097070
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Myrexis Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevirimat |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2010-04-01
- Last updated
- 2010-04-01
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01097070. Inclusion in this directory is not an endorsement.